Literature DB >> 9371524

Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants.

P B Neame1, P Soamboonsrup, B Leber, R F Carter, L Sunisloe, W Patterson, A Orzel, S Bates, J A McBride.   

Abstract

Early diagnosis of t(15;17) acute promyelocytic leukemia (APL) is essential because of the associated disseminated intravascular coagulation and the unique response of the disease to all-trans retinoic acid (ATRA) therapy. Early diagnosis depends primarily on morphological recognition. The French-American-British (FAB) classification, however, does not describe all morphological variations that occur in APL. In 25 cases with evidence of APL confirmed by cytogenetic and/or molecular analysis, we found a heterogeneous morphological group. The most common form of APL was heterogeneous and consisted of various combinations of cells in which hypergranular cells and some cells with multiple Auer rods were obvious. In some cases, one cell predominated. This led to the description of five subcategories. These included the classical FAB M3 with hypergranular cells and multiple Auer rods; the FAB variant with hypogranular bilobed cells; the basophilic cell type of McKenna et al. [Br. J. Haematol 50:201, 1982]; and two additional subtypes, one consisting of differentiated promyelocytes and a few blast cells (M2-like), and the other consisting largely of blast cells and a few early promyelocytes (M1-like). Immunophenotyping revealed a pattern of CD33 and/or CD13 positivity, and CD14 and HLA-DR negativity in 96% of cases. CD2 was positive in the FAB variant and in the subtype with basophilic cells, but negative with other subtypes. Three out of five cases with basophilic cell predominance [McKenna et al.: Br J Haematol 50:201, 1982], and one out of two M2-like cases, responded to ATRA therapy. Awareness of the heterogeneity and the atypical morphologic subtypes found in t(15;17) APL will contribute to improved recognition and early institution of ATRA therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371524     DOI: 10.1002/(sici)1096-8652(199711)56:3<131::aid-ajh1>3.0.co;2-z

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Atypical features in a patient with acute promyelocytic leukaemia: a potential diagnostic pitfall.

Authors:  Muhajir Mohamed; Karen Dun; Julian Grabek
Journal:  BMJ Case Rep       Date:  2013-09-06

2.  A variant acute promyelocytic leukemia with t(11;17) (q23;q12); ZBTB16-RARA showing typical morphology of classical acute promyelocytic leukemia.

Authors:  Sang Bong Han; Jihyang Lim; Yonggoo Kim; Hee-Je Kim; Kyungja Han
Journal:  Korean J Hematol       Date:  2010-06-30

3.  A variant form of acute promyelocytic leukemia with marked myelofibrosis.

Authors:  K Fukuno; H Tsurumi; T Yoshikawa; T Yamada; M Oyama; H Moriwaki
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

Review 4.  New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.

Authors:  Amer M Zeidan; Steven D Gore
Journal:  Clin Cancer Res       Date:  2014-10-01       Impact factor: 12.531

5.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

Authors:  Martin S Tallman; Haesook T Kim; Pau Montesinos; Frederick R Appelbaum; Javier de la Serna; John M Bennett; Guillermo Deben; Clara D Bloomfield; Jose Gonzalez; James H Feusner; Marcos Gonzalez; Robert Gallagher; Jose D Gonzalez-San Miguel; Richard A Larson; Gustavo Milone; Elisabeth Paietta; Chelo Rayon; Jacob M Rowe; Concha Rivas; Charles A Schiffer; Edo Vellenga; Lois Shepherd; James L Slack; Peter H Wiernik; Cheryl L Willman; Miguel A Sanz
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

6.  Clinicopathological features of acute promyelocytic leukemia: an experience in one institute emphasizing the morphological and immunophenotypic changes at the time of relapse.

Authors:  Miyuki Yoshii; Mitsuaki Ishida; Takashi Yoshida; Hiroko Okuno; Ryota Nakanishi; Akiko Horinouchi; Keiko Hodohara; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

7.  Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia.

Authors:  Eun Sun Yoo
Journal:  Korean J Pediatr       Date:  2011-03-31

8.  Down syndrome with microgranular variant of acute promyelocytic leukemia in a child: a case report.

Authors:  Deepali Jain; Tejinder Singh; Prerna Arora
Journal:  J Med Case Rep       Date:  2007-11-24

9.  FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia.

Authors:  Mariko Takenokuchi; Seiji Kawano; Yuji Nakamachi; Yasuyuki Sakota; Meilani Syampurnawati; Katsuyasu Saigo; Eiji Tatsumi; Shunichi Kumagai
Journal:  Hematol Rep       Date:  2012-10-16

10.  High-Throughput Method for Automated Colony and Cell Counting by Digital Image Analysis Based on Edge Detection.

Authors:  Priya Choudhry
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.